In an 84‑kg patient with a new tissue aortic valve and a central line culture growing gram‑positive cocci, what is the appropriate antimicrobial therapy and line management?

Management of Central Line Infection with Gram-Positive Cocci in Patient with Prosthetic Aortic Valve

Remove the central line immediately and start empiric vancomycin while awaiting speciation and susceptibilities, given the patient's prosthetic aortic valve which dramatically increases risk of endocarditis. 1

Immediate Line Management

The central line must be removed. This is non-negotiable for several critical reasons:

• Staphylococcus aureus: If this is the pathogen (most common gram-positive cocci in line infections), nontunneled CVCs suspected as the source should be removed and a new catheter inserted at a different site 1
• Prosthetic valve presence: The patient has a tissue aortic valve, which creates an obligatory indication for aggressive source control to prevent seeding
• Even coagulase-negative staphylococci, while sometimes manageable with catheter retention in other scenarios, warrant removal given the high-risk cardiac substrate 1

Empiric Antimicrobial Therapy

Start vancomycin immediately as empiric therapy while awaiting final identification and susceptibilities 1. Vancomycin covers:

• Methicillin-resistant S. aureus (MRSA)
• Coagulase-negative staphylococci (most are methicillin-resistant)
• Enterococci

Dosing considerations: Target vancomycin trough >15 mg/L, aiming for AUC₂₄/MIC >400 for serious staphylococcal infections 2. This typically requires aggressive dosing in an 84-kg patient (approximately 1.5-2g IV q12h, adjusted by levels).

Antibiotic Adjustment Based on Final Identification

If Staphylococcus aureus (methicillin-susceptible):

• Switch immediately to nafcillin or oxacillin (2g IV q4h) 1
• Vancomycin should NOT be continued for susceptible organisms—it has higher failure rates and slower bacteremia clearance 1
• Alternative: cefazolin 2g IV q8h if penicillin allergy without anaphylaxis

If MRSA:

• Continue vancomycin with aggressive dosing
• If vancomycin MIC ≥2 mcg/mL or persistent bacteremia, consider daptomycin 8-10 mg/kg/day (higher than standard 6 mg/kg for endocarditis risk) 3, 4, 5

If Coagulase-negative staphylococci:

• Continue vancomycin if methicillin-resistant (most are)
• Switch to nafcillin/oxacillin if susceptible 1

If Enterococcus:

• Ampicillin 2g IV q4h if susceptible (preferred over vancomycin)
• Vancomycin if ampicillin-resistant
• Consider infectious disease consultation for vancomycin-resistant enterococci

Critical Next Step: Endocarditis Evaluation

Obtain transesophageal echocardiography (TEE) within 24-48 hours 1. This is mandatory given:

• Prosthetic valve present
• Gram-positive cocci bacteremia (especially if S. aureus)
• TEE is far superior to transthoracic echo for detecting vegetations and should not be skipped 1

Duration of Therapy

If TEE is negative and catheter removed:

• S. aureus: 14 days of systemic antibiotics 1
• Coagulase-negative staphylococci: 5-7 days if catheter removed 1
• Enterococcus: 10-14 days 1

If endocarditis is confirmed:

• 4-6 weeks of IV antibiotics 2, 1
• Cardiac surgery consultation for potential valve intervention

Blood Culture Monitoring

Obtain 2 sets of blood cultures every 24-48 hours until clearance 2. Start counting treatment days from the first negative blood culture 2. Persistent bacteremia beyond 48-72 hours despite appropriate therapy suggests:

• Endocarditis
• Metastatic infection
• Inadequate source control

Key Pitfalls to Avoid

• Do not use vancomycin for methicillin-susceptible organisms—this increases treatment failure 1
• Do not rely on transthoracic echo alone—sensitivity is too low for prosthetic valves 1
• Do not delay line removal—salvage attempts with antibiotics alone have unacceptably high failure rates with S. aureus 1, 6
• Do not underdose vancomycin—target aggressive trough levels given endocarditis risk 2

Infectious Disease Consultation

Obtain ID consultation immediately 2. This case involves multiple high-risk features (prosthetic valve, central line bacteremia, gram-positive cocci) that warrant specialist input for optimal antimicrobial selection and duration decisions.